TriSalus Life Sciences (TLSIW) Stock Price, News & Analysis

Company Overview

TriSalus Life Sciences is an oncology company focused on developing and commercializing therapies and medical technologies for difficult-to-treat solid tumors, particularly liver and pancreatic cancers. The company combines interventional oncology, drug delivery and immunotherapy to address the tumor microenvironment and improve treatment delivery.

TriSalus’ technology platform includes Pressure-Enabled Drug Delivery (PEDD), a method designed to help administer therapies directly into tumors or their associated blood vessels. Its TriNav Infusion System is used in regional, liver-directed procedures and is intended to support more consistent delivery of therapeutic agents to targeted areas.

In addition to its medical-device business, TriSalus is advancing investigational therapies and clinical programs that use localized delivery and immune-based approaches. The company serves hospitals, physicians and patients involved in interventional oncology, with a primary focus on cancer care in the United States. TriSalus Life Sciences is associated with the Nasdaq-listed TLSI securities; TLSIW represents warrants rather than the company’s common stock.

Key Stats

• Today's Range: $0.80 to $0.91
• 50-Day Range: $0.56 to $1.45
• 52-Week Range: $0.44 to $1.85
• Volume: 6,529 shs
• Average Volume: 4,998 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:TLSIW
• CIK: 1826667
• Web: trisaluslifesci.com
• Phone: (415) 336-8917
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $45.08 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A